Growth Hormone: Therapeutic Possibilities—An Overview

Harvey, S.; Martínez-Moreno, Carlos G.

doi:10.3390/ijms19072015

Cited by 5 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…сравнили эффект при применении КМБ-2 и костного морфогенетического белка-6 (КМБ-6) в комбинации с ИФР-1 на протеобластах костной ткани мышей. Результаты показали, что применение ИФР-1 усиливало ИФР-1-индуцированную остеогенную дифференцировку клеток, кроме того, комбинация КМБ-2 с ИФР-1 оказалась эффективнее комбинации КМБ-6 с ИФР-1 [47].…”

Section: ифр-1 и заболевания костно-мышечной системыunclassified

The role of IGF-1/GH in the aging process and the development of age-related diseases

Ilyushchenko¹,

Matchekhina²,

Strazhesko³

et al. 2023

Obes. metabol.

View full text Add to dashboard Cite

One of the most important trends in geroscience is the search for the biomechanisms of aging and geroprotective methods. In recent years, more and more attention has been paid to the role of age-related decline in IGF-1 levels; processes that start with a decrease in the activity of the GH/IGF-1 axis. IGF-1 levels correlate differently with many age-associated diseases: diabetes mellitus, cancer, cardiovascular disease. A decrease in the level of IGF-1 and growth hormone in the elderly can contribute to the deterioration of the course of some pathologies, and also have a protective effect in the occurrence of different nosologies. The possibility of slowing down aging with the help of IGF-1 in basic research led to research aimed at studying the possibility of using IGF-1 preparations and growth hormone in clinical practice to slow down aging. We have studied the literature on the Pubmed platform, Scopus for the past 10 years in order to find some new information regarding influence of IGF-1 on aging, about the association between IGF-1 levels and major age-related diseases. We analyzed data of publications on the role of IGF-1 in aging and the development of age-related diseases. The search was carried out using key words: IGF-1, growth hormone, aging, the review included data from more than 60 publications.

show abstract

Section: ифр-1 и заболевания костно-мышечной системыunclassified

The role of IGF-1/GH in the aging process and the development of age-related diseases

Ilyushchenko¹,

Matchekhina²,

Strazhesko³

et al. 2023

Obes. metabol.

View full text Add to dashboard Cite

show abstract

“…9 IGF-1 is mainly generated from the liver in response to growth hormone (GH) stimulation. 10,11 A lower level of IGF-1 can be caused by liver disease and uncontrolled diabetes mellitus 12 and is linked to IR. 13 IGF-1 plays a crucial role in fetal development, childhood growth, muscle regeneration as well as homeostasis maintenance in adult tissues by regulating cell survival, proliferation, and differentiation.…”

Section: Introductionmentioning

confidence: 99%

“…Insulin‐like growth factor 1 (IGF‐1), also known as somatomedin C, is a protein hormone similar to insulin in molecular structure, and possesses autocrine, paracrine, and endocrine properties 9 . IGF‐1 is mainly generated from the liver in response to growth hormone (GH) stimulation 10,11 . A lower level of IGF‐1 can be caused by liver disease and uncontrolled diabetes mellitus 12 and is linked to IR 13 .…”

Section: Introductionmentioning

confidence: 99%

Astragalus polysaccharide ameliorates insulin resistance in HepG2 cells through activating the STAT5/IGF‐1 pathway

Yue,

Hao,

Wang

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundInsulin resistance (IR) is considered as a major factor initiating type 2 diabetes mellitus and can lead to a reduction in glucose uptake that mainly occurs in the liver. Astragalus polysaccharide (APC), extracted from the traditional Chinese medicine, has been recorded to suppress IR. However, the underlying mechanism remains inadequately explored.MethodsIR was induced in HepG2 cells which further underwent APC treatment. Cell viability was determined by cell counting kit‐8 assay. Pretreatment with AG490, an inhibitor of signal transducer and activator of transcription 5 (STAT5) signaling, was performed for investigating the influence of STAT5 on APC. Glucose uptake level was reflected by 2‐deoxyglucose‐6‐phosphate content determined through colorimetric assay. Expression levels of insulin‐like growth factor 1 (IGF‐1), IGF‐1 receptor (IGF‐1R), phosphorylated‐STAT5/STAT5, and p‐protein kinase B (AKT)/AKT in the cells were assessed by Western blot. Radioimmunoassay (RIA) was used to detect IGF‐1 secretion in the cells.ResultsAPC at doses of 10 and 20 mg increased the viability of HepG2 cells with/without IR induction, and abrogated IR‐induced inhibition of glucose intake. Meanwhile, APC (10 mg) offset IR‐induced inhibition on the expressions of IGF‐1R and IGF‐1, the activation of AKT and STAT5, and the secretion of IGF‐1 in HepG2 cells. More importantly, the reversal effect of APC on IR‐induced alterations in HepG2 cells was counteracted by AG490.ConclusionAPC ameliorates IR in HepG2 cells through activating the STAT5/IGF‐1 pathway.

show abstract

“…The production of biosynthetic GH allows for the treatment of people with its deficiency [7], in low-growth conditions in which GH deficiency is not found, such as Turner syndrome, Prader-Willi syndrome, Noonan syndrome, idiopathic low-growth syndrome and chronic renal failure. STH has also been used in diseases that cause a loss of muscle tissue, cachexia due to HIV, cystic fibrosis, inflammatory bowel disease and neurodegenerative disorders [8]. Registered preparations of STH come in the form of a solution and a powder and solvent for preparing a solution for injection.…”

Section: Introductionmentioning

confidence: 99%

Somatotropin Penetration Testing from Formulations Applied Topically to the Skin

et al. 2023

View full text Add to dashboard Cite

Growth hormone (somatotropin—STH) deficiency therapy requires daily injections of recombinant human growth hormone. The FDA approved treatment with STH with one dose per week for the first time in 2021. However, injectable drug application is accompanied by numerous inconveniences. Therefore, an attempt was made to formulate a less invasive STH formulation for topical application to the skin. A substrate was prepared based on a polymer, methylcellulose (MC), into which STH was introduced at a concentration of 1 mg/g. Simultaneously, formulations were made with STH, to which albumin (ALB) was added at different concentrations: 0.1%, 0.2% and 0.5%. A test of the degree of STH permeation was carried out, as well as the effect of ALB on STH permeation parameters. Selected rheological properties of the formulations obtained were investigated. A test of STH permeation in simulated in vivo conditions through porcine skin indicated a relatively good bioavailability of over 80% and confirmed the effectiveness of MC as a carrier for growth hormone. ALB prolonged the STH penetration rate and increased the penetration degree of STH to 93%. The hydrogels obtained were found to be typical shear-thinning, thixotropic fluids.

show abstract

Growth Hormone: Therapeutic Possibilities—An Overview

Abstract: n/a

Cited by 5 publications

References 39 publications

The role of IGF-1/GH in the aging process and the development of age-related diseases

The role of IGF-1/GH in the aging process and the development of age-related diseases

Astragalus polysaccharide ameliorates insulin resistance in HepG2 cells through activating the STAT5/IGF‐1 pathway

Somatotropin Penetration Testing from Formulations Applied Topically to the Skin

Contact Info

Product

Resources

About